Cargando…

Clinical Implications of the New York Heart Association Classification

BACKGROUND: The New York Heart Association (NYHA) classification has served as a fundamental tool for risk stratification of heart failure (HF) and determines clinical trial eligibility and candidacy for drugs and devices. However, its ability to adequately stratify risk is unclear. METHODS AND RESU...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caraballo, César, Desai, Nihar R., Mulder, Hillary, Alhanti, Brooke, Wilson, F. Perry, Fiuzat, Mona, Felker, G. Michael, Piña, Ileana L., O'Connor, Christopher M., Lindenfeld, Joanne, Januzzi, James L., Cohen, Lawrence S., Ahmad, Tariq
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912957/ https://www.ncbi.nlm.nih.gov/pubmed/31771438 http://dx.doi.org/10.1161/JAHA.119.014240

Ejemplares similares

Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial
por: Chouairi, Fouad, et al.
Publicado: (2021)

Clinical Implications of Cluster Analysis-Based Classification of Acute Decompensated Heart Failure and Correlation with Bedside Hemodynamic Profiles
por: Ahmad, Tariq, et al.
Publicado: (2016)

The influence of comorbidities on achieving an N‐terminal pro‐b‐type natriuretic peptide target: a secondary analysis of the GUIDE‐IT trial
por: Ezekowitz, Justin A., et al.
Publicado: (2021)

Differences in NT‐proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction
por: Daubert, Melissa A., et al.
Publicado: (2021)

Policy and Payment Challenges in the Postpandemic Treatment of Heart Failure: Value-Based Care and Telehealth
por: Piña, Ileana L., et al.
Publicado: (2022)

Managing the economic challenges in the treatment of heart failure
por: Piña, Ileana L., et al.
Publicado: (2021)

Heart Failure Collaboratory Statement on Clinical Trials in the Landscape of COVID-19
por: Abraham, William T., et al.
Publicado: (2020)

Heart Failure Collaboratory Statement on Remote Monitoring and Social Distancing in the Landscape of COVID-19
por: Abraham, William T., et al.
Publicado: (2020)

Mechanistic Efficacy of Sacubitril/Valsartan in Ischemic Versus Nonischemic Heart Failure
por: Mohebi, Reza, et al.
Publicado: (2023)

Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients
por: Ahmad, Tariq, et al.
Publicado: (2018)

Importance of the ‘area under the curve’ from serial NT‐proBNP measurements during treatment with sacubitril/valsartan
por: Mohebi, Reza, et al.
Publicado: (2023)

Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel
por: Psotka, Mitchell A., et al.
Publicado: (2020)

Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan
por: Ibrahim, Nasrien E., et al.
Publicado: (2020)

Sex‐based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
por: Ibrahim, Nasrien E., et al.
Publicado: (2020)

Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF
por: Felker, G. Michael, et al.
Publicado: (2021)

Ischaemia change with revascularisation versus medical therapy in reduced ejection fraction
por: Mentz, Robert J, et al.
Publicado: (2015)

Resourcing Drug Development Commensurate With its Public Health Importance: The Road Ahead
por: Fiuzat, Mona, et al.
Publicado: (2016)

Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials
por: Fiuzat, Mona, et al.
Publicado: (2022)

Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study
por: Januzzi, James L., et al.
Publicado: (2022)

Outcomes in patients with anthracycline‐induced cardiomyopathy undergoing left ventricular assist devices implantation
por: Guha, Avirup, et al.
Publicado: (2021)

Stakeholder Perspectives on Data-Driven Solutions to Address Cardiovascular Disease and Health Equity in New York City
por: Lindenfeld, Zoe, et al.
Publicado: (2023)

Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials
por: Ahmad, Tariq, et al.
Publicado: (2019)

Cumulative Burden of Financial Hardship From Medical Bills Across the Spectrum of Diabetes Mellitus and Atherosclerotic Cardiovascular Disease Among Non‐Elderly Adults in the United States
por: Mszar, Reed, et al.
Publicado: (2020)

COVID-19 infections and outcomes in a live registry of heart failure patients across an integrated health care system
por: Caraballo, César, et al.
Publicado: (2020)

Endovascular Baroreflex Amplification With the MobiusHD Device in Patients With Heart Failure and Reduced Ejection Fraction: Interim Analysis of the First-in-Human Results
por: Piayda, Kerstin, et al.
Publicado: (2022)

Epidemiology and Spatial Emergence of Anaplasmosis, New York, USA, 2010‒2018
por: Russell, Alexis, et al.
Publicado: (2021)

Bourbon Virus Transmission, New York, USA
por: Dupuis, Alan P., et al.
Publicado: (2023)

Hemolytic Uremic Syndrome Incidence in New York
por: Chang, Hwa-Gan H., et al.
Publicado: (2004)

A Novel Treatment for a Rare Cause of Cardiogenic Shock
por: Chowdhury, Mohsin, et al.
Publicado: (2020)

Clinical Profile, Health Care Costs, and Outcomes of Patients Hospitalized for Heart Failure With Severely Reduced Ejection Fraction
por: Harrington, Josephine, et al.
Publicado: (2023)

First Distrtct Dental Society of the State of New York
por: Perry, S. G.
Publicado: (1871)

Beta blocker dose and markers of sympathetic activation in heart failure patients: interrelationships and prognostic significance
por: Cohen‐Solal, Alain, et al.
Publicado: (2017)

Evaluation of ML-Based Clinical Decision Support Tool to Replace an Existing Tool in an Academic Health System: Lessons Learned
por: Woo, Myung, et al.
Publicado: (2020)

Galectin-3 in Heart Failure: More Answers or More Questions?
por: Ahmad, Tariq, et al.
Publicado: (2012)

Supreme Court State of New York: County of New York
por: Hamilton, Thomas L.
Publicado: (1904)

Impact of COVID-19 on Heart Failure Clinical Trials: Insights From the Heart Failure Collaboratory
por: Bhatt, Ankeet S., et al.
Publicado: (2023)

Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure
por: Mezzacappa, Catherine, et al.
Publicado: (2020)

Combinatorial Pharmacogenetic Interactions of Bucindolol and β(1), α(2C) Adrenergic Receptor Polymorphisms
por: O'Connor, Christopher M., et al.
Publicado: (2012)

Evaluation of associations between asthma exacerbations and distance to roadways using geocoded electronic health records data
por: He, Jingyi, et al.
Publicado: (2020)

Prevalence and predictors of no-shows to physical therapy for musculoskeletal conditions
por: Bhavsar, Nrupen A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rk969ugm9t64i5ffekfd93gvlu